While much attention has been focused lately on breakthrough drugs for treating Alzheimer’s disease, Altoida CEO Marc Jones believes their digital assessment technology will play a crucial role in determining, even before first symptoms appear, whether a case of mild cognitive impairment (MCI) will escalate into Alzheimer’s within a year.
According to the Alzheimer’s Association, the number of Americans aged 65 and older living with Alzheimer’s disease is expected to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?